Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10385507" target="_blank" >RIV/00064165:_____/19:10385507 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00112784 RIV/00216208:11110/19:10385507 RIV/00216208:11120/19:43917435 RIV/00216208:11130/19:10385507 and 5 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QzQhdlzwrh" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QzQhdlzwrh</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/ajh.25362" target="_blank" >10.1002/ajh.25362</a>
Alternative languages
Result language
angličtina
Original language name
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
Original language description
Recently, survival benefit of rituximab maintenance (RM) was confirmed in patients with mantle cell lymphoma (MCL) treated with R-DHAP and autologous stem cell transplant (ASCT). Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066) we analyzed outcome of MCL patients treated with the Nordic MCL2 protocol followed by ASCT and RM or observation. The cohort consisted of 143 consecutive patients with median age 56 years, and with MIPI low, intermediate and high risk in 41%, 38% and 21% patients, respectively. Overall response rate (ORR) after induction in the whole cohort was 93% (67.1% CRs). 138 patients completed induction and 119 were transplanted. ORR after ASCT was 92.4% (81.5% CRs). From 130 patients without progression within 120 days after the last therapy delivery (in 112 pts after stem cell transfer, in 18 pts after the last cycle of induction), 66 initiated RM, and 64 were observed. With a median follow up 4.1 years median PFS was 9.8 years (5-y PFS and OS 66.2% and 74.4%, respectively) and median OS was not reached for the whole cohort. RM compared to observation significantly reduced risk of progression (5-y PFS 82.9% vs. 63.3%, p 0.004, HR 0.36, 95% CI 0.21 - 0.74), but the difference was not significant for OS. There was no difference in PFS in RM group between patients with and without ASCT. MIPI and splenomegaly independently correlated with shorter PFS and OS.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV17-28980A" target="_blank" >NV17-28980A: New prognostic and predictive markers in patients with mantle cell lymphoma at diagnosis and on treatment</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Hematology
ISSN
0361-8609
e-ISSN
—
Volume of the periodical
94
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
"e50"-"e53"
UT code for WoS article
000455234700005
EID of the result in the Scopus database
2-s2.0-85058416954